Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: Nine years of experience at a single center

Cancer

Volumn 119, Issue 5, 2013, Pages 978-985

  Wang, Yu ^a   Liu, Dai Hong ^a   Liu, Kai Yan ^a   Xu, Lan Ping ^a   Zhang, Xiao Hui ^a   Han, Wei ^a   Chen, Huan ^a   Chen, Yu Hong ^a   Wang, Feng Rong ^a   Wang, Jing Zhi ^a   Sun, Yu Qian ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

allogeneic; haploidentical; hematopoietic stem cell transplantation; human leukocyte antigen; mismatched

Indexed keywords

ACLACINOMYCIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SEMUSTINE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD DONOR; CANCER RISK; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; IN VITRO STUDY; INCIDENCE; LONG TERM SURVIVAL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL RATE; T CELL DEPLETION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; LEUKEMIA; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874272748     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27761     Document Type: Article

References (30)

1. Friedrich W, Goldmann SF, Vetter U, et al. Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T-cell-depleted bone marrow. Lancet. 1984; 1: 761-764.
2. Aversa F,. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant. 2008; 41: 473-481.
3. Huang XJ,. Current status of haploidentical stem cell transplantation for leukemia. J Hematol Oncol. 2008; 1: 27.
4. Kang Y, Chao NJ, Aversa F,. Unmanipulated or CD34 selected haplotype mismatched transplants. Curr Opin Hematol. 2008; 15: 561-567.
5. Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006; 38: 291-297.
6. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLAmismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006; 107: 3065-3073.
7. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005; 23: 3447-3454.
8. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14: 641-650.
9. Brodsky RA, Luznik L, Bolanos-Meade J, Leffell MS, Jones RJ, Fuchs EJ,. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008; 42: 523-527.
10. Ogawa H, Ikegame K, Kaida K, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol. 2008; 36: 1-8.
11. Ichinohe T, Uchiyama T, Shimazaki C, et al.; Japanese Collaborative Study Group for NIMA-Complementary Haploidentical Stem Cell Transplantation. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood. 2004; 104: 3821-3828.
12. van Rood JJ, Loberiza FR Jr, Zhang MJ, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 2002; 99: 1572-1577.
13. Huang XJ, Liu DH, Liu KY, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2009; 15: 257-265.
14. Huang XJ, Xu LP, Liu KY, et al. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitroTcell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med. 2008; 40: 444-455.
15. Liu DH, Huang XJ, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biol Blood Marrow Transplant. 2008; 14: 469-477.
16. Huang XJ, Liu DH, Liu KY, et al. Modified donor lymphocyte infusion after HLA-mismatched/haplo-identical T-cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol. 2008; 28: 276-283.
17. Zhao XS, Liu YR, Zhu HH, et al. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2012; 91: 183-192.
18. Zhao XS, Jin S, Zhu HH, et al. Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2012; 47: 499-507.
19. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W,. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haplo- identical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007; 92: 414-417.
20. Chen H, Liu KY, Xu LP, et al. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Chin Med J. 2011; 124: 246-252.
21. Scrucca L, Santucci A, Aversa F,. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant. 2010; 45: 1388-1395.
22. Huang XJ, Xu LP, Liu KY, et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res. 2009; 15: 4777-4783.
23. Chang YJ, Xu LP, Liu DH, et al. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD341 cell dose and disease status. Biol Blood Marrow Transplant. 2009; 15: 632-638
24. Obama K, Utsunomiya A, Takatsuka Y, Takemoto Y,. Reduced-intensity non-T-cell depleted HLA haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance. Bone Marrow Transplant. 2004; 34: 897-899.
25. Matsuoka K, Ichinohe T, Hashimoto D, Asakura S, Tanimoto M, Teshima T,. Fetal tolerance to maternal antigens improves the outcome of allogeneic bone marrow transplantation by a CD4+ CD25+ T-cell-dependent mechanism. Blood. 2006; 107: 404-409.
26. Kim HJ, Park SJ, Im HW, et al. The association of HLA antigen and GVHD in allogeneic hemopoietic stem cell transplantation with histocompatible sibling donor: a single-center experience in Korea. Int J Hematol. 2002; 76: 267-271.
27. Huo MR, Xu LP, Li D, et al. The effect of HLA disparity on clinical outcome after HLA-haploidentical blood and marrow transplantation. Clin Transplant. 2012; 26: 284-291.
28. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant. 2000; 26: 397-404.
29. Wang Y, Liu DH, Xu LP, et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant. 2012; 47: 1099-1104.
30. Wang Y, Liu DH, Xu LP, et al. Superior graft-versus-leukemia effect associated with transplantation of haplo-identical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historical comparison. Biol Blood Marrow Transplant. 2011; 17: 821-830.